Phosphoproteomics identifies PI3K inhibitor-selective adaptive responses in pancreatic cancer cell therapy and resistance
C. Cintas, T. Douche, Z. Dantes, E. Mouton-Barbosa, M.-P. Bousquet, C. Cayron, N. Therville, F. Pont, F. Ramos-Delgado, C. Guyon, B. Garmy-Susini, P. Cappello, O. Burlet-Schiltz, E. Hirsch, A. Gomez-Brouchet, , J. Guillermet-Guibert
This study identifies adaptive phosphoprotein responses to isoform-selective PI3K inhibitors in pancreatic cancer, showing that combination therapy can overcome resistance.
bioRxiv · Oct 8, 2020Cancer Biology